SureshSakkaraiRamalingamMDFACP, FASCO

Oncology • Atlanta, GA

Hematologic Oncology, Thoracic Cancer

Executive Director, Winship Cancer Institute of Emory University

Join to view full profile

Dr. Ramalingam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Ramalingam's full profile

Already have an account?

Office
1365 Clifton Road NE
C-4014E
Atlanta, GA 30322
Phone+1 404-778-5378

Fax+1 404-778-5520
Is this information wrong?

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
Wayne State University School of MedicineResidency, Internal Medicine, 1993 - 1996
Kilpauk Medical CollegeClass of 1992

Certifications & Licensure

GA State Medical License 2007 - 2025
PA State Medical License 2000 - 2008
MI State Medical License 1995 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor Start of enrollment: 2004 May 01
Completed
Phase 1
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Start of enrollment: 2005 Oct 13
Completed
Phase 2
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors Start of enrollment: 2005 Jul 01
Completed
Phase 1
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Start of enrollment: 2006 Jun 01
Completed
Phase 2
Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2006 Nov 01
Completed
Phase 1
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Nov 01
Terminated
Phase 1, Phase 2
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction Start of enrollment: 2007 Jun 01
Completed
Phase 1
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies Start of enrollment: 2012 May 01
Withdrawn
Phase 1
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) Start of enrollment: 2018 Jul 19
Active, not recruiting
Phase 3
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 12
Recruiting
Phase 1, Phase 2
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Start of enrollment: 2019 May 14
Active, not recruiting
Phase 1, Phase 2
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Start of enrollment: 2019 Oct 08
Active, not recruiting
Phase 3
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2022 Nov 01
Recruiting
Early Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
Zhen Chen, Karin A Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana Leal, Suresh S Ramalingam, Shi-Yong Sun> ;The Journal of Clinical Investigation. 2024 Mar 7
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Riely, G., Smit, E., Ahn, M., Felip, E., Ramalingam, S., Tsao, A., Johnson, M., Gelsomino, F., Esper, R., Nadal, E., Offin, M., Provencio, M., Clarke, J., Hussein, M.,...> ;Future Oncology. 2024 Feb 15
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
David E Gerber, Yating Wang, Suresh S Ramalingam, Sheena Bhalla, Zhuoxin Sun, Hossein Borghaei, Julie R Brahmer, Joan H Schiller> ;The Oncologist. 2024 Apr 4
2 citations
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S Ramalingam> ;Lung Cancer. 2024 Jan 1
Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy.
Masao Hashimoto, Suresh S Ramalingam, Rafi Ahmed> ;Trends in Cancer. 2024 Apr 1
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Jürgen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh S Ramalingam, Christo...> ;Future Oncology. 2024 Jan 1
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
Martin Johnson, Carlos Serra Traynor, Karthick Vishwanathan, Philip Overend, Ryan Hartmaier, Aleksandra Markovets, Juliann Chmielecki, Ganesh M Mugundu, J Carl Barrett...> ;Clinical Pharmacology and Therapeutics. 2024 Feb 1
1 citations
Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade.
Annapaola Mariniello, Tahseen H Nasti, Daniel Y Chang, Masao Hashimoto, Sakshi Malik, Daniel McManus, Judong Lee, Donald McGuire, Maria A Cardenas, Pablo Umana, Valeri...> ;Clinical Cancer Research. 2023 Nov 22
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
Valanparambil, R., Lai, L., Johns, M., Davis-Gardner, M., Linderman, S., McPherson, T., Chang, A., Akhtar, A., Gamarra, E., Matia, H., McCook-Veal, A., Switchenko, J.,...> ;NPJ Vaccines. 2023 Nov 21
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid B...
Jhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, Xiangning Huang, Alexander Kohlmann, Rachel Hodge, Yuri Rukazenkov, Juliann Chmielecki, Carin R Espenschied, Marti...> ;The Journal of Molecular Diagnostics. 2024 Jan 1
Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.
Ananda M Rodilla, Rajesh M Valanparambil, Philip C Mack, Chih-Yuan Hsu, Jazz Cagan, Sooyun C Tavolacci, Juan Manuel Carreño, Rachel Brody, Amy Moore, Jennifer C King, ...> ;Cancer Cell. 2023 Nov 13
3 citations
Characteristics and anatomic location of PD-1TCF1stem-like CD8 T cells in chronic viral infection and cancer.
Se Jin Im, Rebecca C Obeng, Tahseen H Nasti, Daniel McManus, Alice O Kamphorst, Sivaram Gunisetty, Nataliya Prokhnevska, Jennifer W Carlisle, Ke Yu, Gabriel L Sica, Lu...> ;Proceedings of the National Academy of Sciences of the United States of America. 2023 Oct 10
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced- or-Rearranged NSCLC: A Brief Report.
Rohit Thummalapalli, Noura J Choudhury, Fiona Ehrich, Tyler Beardslee, Danielle Brazel, Shannon S Zhang, Shelby Merchant, Monica F Chen, Glenn Heller, Suresh S Ramalin...> ;JTO Clinical and Research Reports. 2023 Aug 1
4 citations
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analy...
Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita M...> ;Clinical Cancer Research. 2023 Sep 1
1 citations
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
Neal S McCall, James R Janopaul-Naylor, H Scott McGinnis, Aparna H Kesarwala, Sibo Tian, William A Stokes, Joseph W Shelton, Conor E Steuer, Jennifer W Carlisle, Ticia...> ;Cancer. 2023 Dec 1
Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer.
Junghui Koo, Chang-Soo Seong, Rebecca E Parker, Bhakti Dwivedi, Robert A Arthur, Ashok Reddy Dinasarapu, H Richard Johnston, Henry Claussen, Carol Tucker-Burden, Sures...> ;Biorxiv. 2023 Jun 14
6 citations
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With-Mutant Metastatic Non-Small-Cell Lung Cancer.
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Micha...> ;Journal of Clinical Oncology. 2023 Jul 20
Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander T...> ;Nature Communications. 2023 Jun 1
10 citations
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Zurawski, Sang-We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Pluzanski, ...> ;Journal of Thoracic Oncology. 2023 Aug 1
Cancer Turns 75!
Suresh S Ramalingam> ;Cancer. 2023 Jul 1
14 citations
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With PretreatedG12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Jürgen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh S Ramalingam, Christo...> ;Journal of Clinical Oncology. 2023 Jun 20
32 citations
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander T...> ;Nature Communications. 2023 Feb 27
18 citations
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna...> ;Nature Communications. 2023 Feb 27
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strate...
Sanjay Popat, Myung-Ju Ahn, Simon Ekman, Natasha B Leighl, Suresh S Ramalingam, Thanyanan Reungwetwattana, Shankar Siva, Masahiro Tsuboi, Yi-Long Wu, James Chih-Hsin Yang> ;Targeted Oncology. 2023 Mar 1
64 citations
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASmutation: a randomised, open-label, phase 3 trial.
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, Anne-Marie C Dingemans, Giannis Mountzios, Miklos Pless, Jürgen Wolf, Martin Schuler, Hervé Lena, Ferd...> ;Lancet. 2023 Mar 4
Join now to see all

Journal Articles

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative Analysis
Rathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
Targeted Sequencing and Intracranial Outcomes of Patients with Lung Adenocarcinoma Brain Metastases Treated with Radiotherapy
Gabriel L Sica, Matthew J Ferris, Walter J Curran, Shannon Kahn, Suresh S Ramalingam, Pretesh R Patel, Rathi N Pillai, Robert H Press, Jim Zhong, Conor E Steuer, Taofe..., Cancer
Predictive Biomarkers for Response to EGFR-Directed Monoclonal Antibodies for Advanced Squamous Cell Lung Cancer
D R Spigel, E S Kim, S S Ramalingam, M A Socinski, C Obasaju, C J Langer, R B Natale, P D Bonomi, H Wakelee, Annals of Oncology
Join now to see all

Lectures

ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
2019 ASCO Annual Meeting - 6/1/2019

Other

How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung Cancer
Suresh Ramalingam, MD, Op-Med
https://www.doximity.com/articles/35d1fb9e-f71f-4645-839f-870e7b27ebe0
UpToDate, Wolters Kluwer Health - 2012-10-04

Authored Content

How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung CancerOctober 2018

Press Mentions

Winship Cancer Institute at Emory Midtown, AtlantaMay 9th, 2023
New Winship Cancer Institute at Emory Midtown to Open for Patients May 9May 4th, 2023
Atlanta Names City's 22 Most Powerful Healthcare LeadersJanuary 30th, 2023
Join now to see all